Reblozyl Approved to Treat Anemia in ESA-Naive, Lower-Risk MDS
Reblozyl (luspatercept-aamt) is approved as first-line treatment for anemia in adults with very low- to intermediate-risk MDS.
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reblozyl (luspatercept-aamt) is approved as first-line treatment for anemia in adults with very low- to intermediate-risk MDS.
Investigators highlighted an association between treatment retention over time and the out-of-pocket cost for patients with hepatic encephalopathy taking rifaximin.
In the fight against health care-associated infections, EHHCM systems are a key weapon.
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority of...
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipo...